HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)

丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)

• 批准号: 7719421
• 负责人: Gregory Thomas Everson
• 金额: $ 1.78万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719421
• 关键词: Adverse effects; Affect; Antiviral Agents; Blood; Blood specimen; Chronic Hepatitis C; Cirrhosis; Clinic Visits; Coin; Computer Retrieval of Information on Scientific Projects Database; Enrollment; Esophagus; Funding; Grant; Hemorrhage; Hepatitis; Hepatitis C; Injection of therapeutic agent; Institution; Interferons; Maintenance; Maintenance Therapy; Malignant neoplasm of liver; Patients; Pharmaceutical Preparations; Phase; Procedures; Quality of life; Questionnaires; Recording of previous events; Research; Research Personnel; Resources; Ribavirin; Risk; Screening procedure; Source; Standards of Weights and Measures; Stomach; Stream; United States; United States Food and Drug Administration; United States National Institutes of Health; Varicosity; Veins; Viral; Visit; Week; follow-up; liver biopsy; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hepatitis C affects about 4 million people in the United States and leads to cirrhosis and liver cancer after many years, in some patients. Treatment with interferon, alone or in combination with a second anti-viral agent ribavirin has been approved by the Food and Drug Administration and is now considered standard therapy for chronic hepatitis C. A slow release form of interferon, called PEG-interferon, remains in the blood stream for one week and gives better results than interferon alone, with fewer injections required. The present study is aimed at patients who have received previous treatment and failed to clear hepatitis C. Patients who meet entry criteria, and are enrolled in the trial, will first be treated with the combination of PEG Interferon plus ribavirin. Responders to this treatment will be given a full one year of therapy. Nonresponders, after 24 weeks of the combination treatment, will be entered into the study of maintenance therapy. Nonresponders will be evenly assigned (by a procedure similar to the toss of a coin) to either maintenance with PEG Interferon (treatment) or no treatment (observation). Follow-up will be identical for the treatment and observation groups and will require 3-monthly visits for 3 1/2 years with 6 months follow-up. Each visit will include history, exam, quality-of-life questionnaire, and blood drawing. Liver biopsies will be performed at two and four years following start of the initial phase. Some patients will undergo endoscopic examination of the esophagus and stomach for varices, large veins at risk for bleed. Risks encountered may include side effects of study medications, that involved in obtaining blood samples, and that of liver biopsy at year 2 and at end of study. Patients will be required to attend two screening visits, plus clinic visits at routine intervals over the entire course of the study.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在美国，丙型肝炎影响着大约400万人，并在许多年后导致肝硬变和肝癌，在一些患者中。单独使用干扰素或与第二种抗病毒药物利巴韦林联合治疗已获美国食品和药物管理局批准，现在被认为是慢性丙型肝炎的标准治疗方法。一种名为聚乙二醇干扰素的缓释干扰素在血液中保留一周，比单独使用干扰素效果更好，所需注射更少。本研究的目标是那些以前接受过治疗但未能清除丙型肝炎的患者。符合入选标准并参加试验的患者将首先接受聚乙二醇干扰素和利巴韦林的联合治疗。这种治疗的应答者将接受整整一年的治疗。在联合治疗24周后，无应答者将进入维持治疗研究。无反应者将被平均分配(通过类似于掷硬币的程序)，要么接受聚乙二醇干扰素(治疗)维持治疗，要么不接受治疗(观察)。治疗组和观察组的随访将是相同的，需要3个月的随访，为期3年半，6个月的随访。每次访问将包括历史、考试、生活质量问卷和抽血。肝活检将在初始阶段开始后的两年和四年进行。一些患者将接受食道和胃的内窥镜检查，看是否有静脉曲张，大静脉有出血的风险。遇到的风险可能包括研究药物的副作用，包括获取血液样本的副作用，以及在第二年和研究结束时进行肝活检的副作用。患者将被要求参加两次筛查访问，以及在整个研究过程中定期进行诊所访问。